Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 72 points (-0.5%) at 15,564 as of Friday, Sept. 20, 2013, 12:54 PM ET. The NYSE advances/declines ratio sits at 854 issues advancing vs. 2,087 declining with 92 unchanged. The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Regeneron Pharmaceuticals ( REGN), down 0.9%, and Valeant Pharmaceuticals International ( VRX), down 0.9%. Top gainers within the industry include Allergan ( AGN), up 1.7%, Shire ( SHPG), up 1.1%, Alexion Pharmaceuticals ( ALXN), up 1.1%, GlaxoSmithKline ( GSK), up 0.7% and Sanofi ( SNY), up 0.7%. TheStreet would like to highlight 4 stocks pushing the industry lower today: 4. Ariad Pharmaceuticals ( ARIA) is one of the companies pushing the Drugs industry lower today. As of noon trading, Ariad Pharmaceuticals is down $1.02 (-4.8%) to $20.47 on average volume. Thus far, 1.0 million shares of Ariad Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $20.43-$21.47 after having opened the day at $21.46 as compared to the previous trading day's close of $21.49. ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals has a market cap of $3.9 billion and is part of the health care sector. Shares are up 8.8% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Ariad Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Ariad Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Ariad Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.